CB0501

CB0501 is a preclinical-stage monoclonal antibody being developed by CellmAbs as an immunotherapy for the treatment of various cancers. It specifically targets cancer-specific glycans, which are carbohydrate structures on the surface of tumor cells that differ significantly from those found on healthy tissues. By binding to these unique glyco-targets, CB0501 is designed to trigger an immune response against the malignancy. The program is part of CellmAbs' proprietary platform focused on the discovery of tumor-associated glycans and the development of high-affinity antibodies to exploit these targets for precision oncology.